HEAR BROOKE'S STORY
An AFINITOR patient talks about her diagnosis with kidney angiomyolipoma with TSC and how she is managing today.
Savings With the AFINITOR Co-Pay Card
Novartis Pharmaceuticals Corporation is committed to helping make treatment with as affordable as possible. For patients with commercial insurance, we offer the AFINITOR Co-Pay Card, which may help eligible patients lower out-of-pocket costs for their treatment.
How may the AFINITOR Co-Pay Card help with my out-of-pocket costs?
For most eligible patients, the co-pay for your AFINITOR prescription will be no more than $25 per month. Novartis will pay the remainder of your co-pay or coinsurance for AFINITOR up to a yearly maximum of $15,000. This program expires on December 31, 2017.
To find out if you are eligible to
save on your next prescription
Terms and Conditions
Valid only for those with commercial insurance. Offer not valid under Medicare, Medicaid, or any other federal or state program. Offer not valid for cash-paying patients, where product is not covered by patient’s commercial insurance, or where plan reimburses you for entire cost of your prescription drug. Offer is not valid where prohibited by law. Valid only in the United States and Puerto Rico. This program is not health insurance. Offer may not be combined with any other rebate, coupon, or offer. This card is the property of Novartis Pharmaceuticals Corporation and must be returned upon request. Novartis reserves the right to rescind, revoke, or amend the program without notice. Patient certifies responsibility for complying with applicable limitations, if any, of any commercial insurance and reporting receipt, of program rewards, if necessary, to any commercial insurer. This offer expires on December 31, 2017.
Present this offer and your insurance card along with a valid prescription at any participating pharmacy or through mail order. Patients with commercial insurance are responsible for $25 for a 28-day supply and Novartis pays up to $15,000 per calendar year. If patient reaches the maximum annual cap per calendar year of $15,000, patient will be responsible for the difference. Offer expires December 31, 2017. Patient questions should be directed to: 877-577-7756.
When you use this offer, you are certifying that you understand the program rules, regulations, and terms and conditions, and that you will disclose and report the use of this offer as may be required by your insurer. You are not eligible if prescriptions are paid by any federal or state program, or where prohibited by law; and you will otherwise comply with the terms and conditions above.
A NONSURGICAL TREATMENT FOR AML ASSOCIATED WITH TSC
AFINITOR® (everolimus) Tablets is a prescription medicine used to treat adults with a kidney tumor called angiomyolipoma, seen with a genetic condition called tuberous sclerosis complex (TSC), when their kidney tumor does not require surgery right away.
Important Safety Information
AFINITOR can cause serious side effects, including lung or breathing problems, infections, and kidney failure, which can lead to death. Patients who take an angiotensin-converting enzyme (ACE) inhibitor medicine during treatment with AFINITOR are at a possible increased risk for a type of allergic reaction called angioedema. AFINITOR can cause incisions to heal slowly or not heal well. Mouth ulcers and mouth sores are common side effects, occurring in up to 78% of patients taking AFINITOR. AFINITOR can affect blood cell counts, kidney and liver function, and blood sugar and cholesterol levels. Regular blood tests should be performed before starting AFINITOR and as needed during treatment to check blood cell count, kidney and liver function, blood sugar and cholesterol levels. For SEGA patients, blood tests to see how much AFINITOR is in the blood should also be performed.
Please see additional
Important Safety Information.
Please see full Prescribing Information for AFINITOR, including Patient Information.